




RealRate

PHARMACEUTICAL 2015

Lixte Biotechnology Holdings INC
Rank 264 of 274



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lixte Biotechnology Holdings INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lixte Biotechnology Holdings INC compared to the market average is the variable Cost of Goods Sold, increasing the Economic Capital Ratio by 0.97% points. The greatest weakness of Lixte Biotechnology Holdings INC is the variable Assets, reducing the Economic Capital Ratio by 127% points.

The company's Economic Capital Ratio, given in the ranking table, is 14%, being 240% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	539
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	273
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	363
Other Liabilities	0
Other Net Income	0.066
Other Revenues	0
Property and Equipment	0
Research and Development	1,118
Selling, General and Administrative Expense	1,285

Output Variable	Value in 1000 USD
Assets	539
Liabilities	273
Expenses	2,766
Revenues	0
Stockholders Equity	266
Net Income	-2,766
Comprehensive Net Income	-2,766
BaseVar	1,790
ECR before Limited Liability	-538%
Economic Capital Ratio	14%